

SATURDAY 9 MARCH

13:00 – 13:05 Opening
Auditorium 2

13:05 – 14:30 **Lessons to be learned from national and international research infrastructures**
Chairs: Dirk Arnold, Helder Mansinho

13:05 Dutch T1 CRC working group
Leon Moons, the Netherlands

13:12 French GRECCAR Study Group
Quentin Denost, France

13:19 National Cancer Research Institute - Colorectal Cancer Clinical Studies Group
Richard Adams, United Kingdom

13:26 Danish Colorectal Cancer Group
Lene Iversen, Denmark

13:33 Dutch Colorectal Cancer Group // PLCRC
Pieter Tanis & Geraldine Vink, the Netherlands

13:47 Italian Intergroup structure and projects
Sara Lonardi, Italy

13:54 German AIO group
Volker Heinemann, Germany

14:01 Lessons to be learned from national and international research infrastructures
-Portuguese GICD study group
Hélder Mansinho, Portugal

14:08 EORTC GI group
Marc Peeters, Belgium

14:15 Discussion

14:30 – 15:00 Break

15:00 – 16:00 **Sponsored symposium Servier**
See page 17

16:00 – 18:00 **Discussing areas of controversy**
Chair: Hans de Wilt

16:00 In primary treatment rectal cancer
David Sebag Montefiore, United Kingdom

SATURDAY 9 MARCH

- 16:25 In primary treatment colon cancer
Pieter Tanis, the Netherlands
- 16:50 What is known and where are the major needs? In local treatments of metastases
Interventional Radiology
Kees Verhoef, the Netherlands
- 17:05 In local treatments of metastases Interventional Radiology
Martijn Meijerink, the Netherlands
- 17:20 Local treatments in Colorectal metastasis: the role of radiotherapy.
State of art and future prospective
Veronica Dell'Acqua, Italy
- 17:35 In systemic treatment
Dirk Arnold, Portugal
- 17:50 Discussion
- 18:00 – 18:30 DCCG lecture**
Chairs: Dirk Arnold, Pieter Tanis
- 18:00 Colon cancer: What is the best approach to understand the disease?
Louis Vermeulen, the Netherlands
- 18:30 – 19:30 Welcome reception**

SUNDAY 10 MARCH

08:15 – 09:30
Auditorium 2

Session 1: Challenges in screen detected early cancers
Chair: Leon Moons

- 08:15 S1.1 Prediction models for lymph node metastasis
Miangele Lacle, the Netherlands
- 08:35 S1.2 Screen detected early cancers: evaluation of the resection margin-
is 1 mm sufficient?
Maurice Loughrey, Ireland
- 08:55 S1.3 What is coming next in the prediction of LNM-
Cord Langner, Austria
- 09:15 Discussion

09:30 – 10:45

**Session 2: What's new in diagnostic imaging –
and what are the therapeutic consequences?**
Chairs: Regina Beets-Tan, Pieter Tanis

- 09:30 S2.1 Locoregional staging of colon and rectal cancer
Regina Beets-Tan, the Netherlands
- 09:50 S2.2 Imaging modalities for liver metastases
Doenja Lambregts, the Netherlands
- 10:10 S2.3 New diagnostic tools: radiomics, “deep learning” – really helpful?
Philippe Lambin, the Netherlands
- 10:30 Discussion

10:30 – 16:30

PARALLEL PROGRAM – GASTROENTEROLOGY
See page 11

10:45 – 11:15

Break

11:15 – 12:30

Session 3: State of the art and development in neo-adjuvant treatment
Chairs: Jeroen Buijsen, Kees Verhoef

- 11:15 S3.1 Difference between cCR after CRT for advanced rectal cancer and
aiming for cCR with CRT in early rectal cancer
Rob Glynne-Jones, United Kingdom
- 11:35 S3.2 Is chemotherapy going to replace radiotherapy in rectal cancer?
David Sebag Montefiore, United Kingdom
- 11:55 S3.3 Deciding on further local treatment after induction therapy for local
and metastatic disease; value and timing of re-staging modalities
Geerard Beets, the Netherlands

SUNDAY 10 MARCH

12:15		Discussion
12:30 – 14:00		Lunch & Poster Presentations (odd numbers)
12:45 – 13:45		CRC Group Meetings / Trial Meetings / Consensus or Guideline initiatives
12:45 room 1.05	B1.1	InterAACT: A global initiative in anal cancer <i>Sheela Rao, United Kingdom</i>
12:45 room 1.06	B1.2	Presentation of CIREL and CIEMAR registries <i>Philippe Pereira, Germany</i>
12:45 room 1.07	B1.3	Translational research: from bench to bedside and back <i>Chair: Onno Kranenburg</i>
12:45	B1.3.1	From Tissue towards Liquid biopsy: current status <i>Marc Peeters, Belgium</i>
13:00	B1.3.2	The serrated pathway: implications for research <i>Iris Nagtegaal, the Netherlands</i>
13:15	B1.3.3	Organoid models to improve intraperitoneal chemotherapy <i>Onno Kranenburg, the Netherlands</i>
13:30	B1.3.4	Circulating tumor DNA as biomarker in colorectal cancer: turning research into care <i>Remond Fijneman, the Netherlands</i>
14:00 – 15:00		Session 4: Case discussion with expert panel Expert panel: <i>Kees Verhoef, Marc Peeters, Hugo Pinto Marques, Gero Puhl, Sara Lonardi, Pieter Tanis</i>
14:00	S4.1	Case on the edge of liver surgery for mCRC <i>Hugo Pinto Marques, Portugal</i>
14:15	S4.2	Case on the edge of multimodality treatment of mCRC <i>Gero Puhl, Germany</i>
14:30		Panel discussion
15:00 – 16:00		Session 5: Translational research: From markers to decisions <i>Chairs: Onno Kranenburg, Karen-Lise Garm Spindler</i>
15:00	S5.1	Clinical implications of “liquid” markers (ctDNA) for treatment selection and response evaluation <i>Karen-Lise Spindler, Denmark</i>

SUNDAY 10 MARCH

15:20	S5.2	Molecular subtypes in colorectal cancer: CMS and beyond <i>Louis Vermeulen, the Netherlands</i>
15:40	S5.3	Organoids to assess treatment response <i>Nicola Valeri, United Kingdom</i>
16:00 – 16:30		Break
16:30 – 17:45		Session 6: What's new in diagnostic and therapeutic endoscopy? <i>Chairs: Leon Moons, Pieter Tanis</i>
16:30	S6.1	State of the art optical diagnosis of polyps <i>Yara Backes, the Netherlands</i>
16:50	S6.2	Endoscopic and surgical techniques for local excision in rectal cancer, what should we do? <i>Francisco Baldaque Silva, Sweden</i>
17:10	S6.3	Endoscopic and hybrid techniques for local excision of colon cancer <i>Leon Moons, the Netherlands</i>
17:30		Discussion
19:00		Dinner <i>See page 14</i>

MONDAY 11 MARCH

08:15 – 09:30
Auditorium 2

Session 7: Future of primary rectal cancer treatment
Chair: Kees Verhoef

- 08:15 S7.1 Role of external beam and endoluminal radiation boosting in rectal cancer
Maaike Berbeé, the Netherlands
- 08:35 S7.2 Challenges in rectal cancer surgery; which problems have to be solved?
Roel Hompes, the Netherlands
- 08:55 S7.3 Locally recurrent rectal cancer; multimodality approach
Quentin Denost, France
- 09:15 Discussion

09:30 – 10:45

Session 8: Systemic therapy in the metastatic setting – state of the art and future
Chairs: Richard Adams, Hugo Pinto Marques

- 09:30 S8.1 Targeting RAS mutated tumors
Volker Heinemann, Germany
- 09:50 S8.2 Prognostic/predictive value of molecular and clinical factors: What makes the difference?
Teresa Macarulla, Spain
- 10:10 S8.3 Feasibility and outcomes of a national expert panel to determine secondary resectability in patients with initially unresectable colorectal liver metastases (CRLM)
Karen Bolhuis, the Netherlands
- 10:30 Discussion

09:45

RADIOLOGY PARALLEL PROGRAM
See page 12

10:45 – 11:15

Break

11:15 – 12:30

Session 9: Colorectal cancer and the immune system
Chair: Dirk Arnold

- 11:15 S9.1 What are the new drugs in the field of immunotherapy?
Guillem Argiles, Spain
- 11:35 S9.2 What are the diagnostic tools and novel concepts of cancer evolution?
Jerome Galon, France
- 11:55 S9.3 What are the effects that are interfering with local or current treatments?
Miriam Chalabi, the Netherlands
- 12:15 Discussion

12:30 – 14:00

Lunch & Poster Presentations (even numbers)

MONDAY 11 MARCH

12:45 – 13:45
Auditorium 2

Best abstract session

Chairs: Rolf Sijmons, Jeroen Buijsen

- | | | |
|-------|------|---|
| 12:45 | 00.1 | Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
<i>Anders Boysen, Denmark</i> |
| 12:55 | 00.2 | Outcomes of J-pouch vs side-to-end vs end-to-end colorectal anastomoses after total mesorectal excision for rectal carcinoma: a prospective trial
<i>Arsen Rasulov, Russia</i> |
| 13:05 | 00.3 | Brachytherapy boost for rectal cancer as a part of curative treatment - retrospective study
<i>Manuel Louro, Portugal</i> |
| 13:15 | 00.4 | Is decompressing stoma a better alternative than stent as bridge to surgery for left-sided obstructive colon cancer
<i>Joyce Veld, the Netherlands</i> |
| 13:25 | 00.5 | The role of induction chemotherapy as an addition to the neoadjuvant treatment for locally recurrent rectal cancer
<i>Eva Voogt, the Netherlands</i> |
| 13:35 | 00.6 | MR-Guided radiation therapy fo locally advanced rectal (LARC) cancer by Mridian?: A monoinstitutional experience and future perspectives
<i>Giuditta Chiloiro, Italy</i> |

14:00 – 15:15

Session 10: Genetics

Chairs: Rolf Sijmons, Richard Houlston

- | | | |
|-------|-------|--|
| 14:00 | S10.1 | Update: the genetic differential diagnosis of polyposis and CRC
<i>Maartje Nielsen, the Netherlands</i> |
| 14:20 | S10.2 | Predicting CRC risk: from tumor syndromes genes to polygenic risk scores
<i>Richard Houlston, United Kingdom</i> |
| 14:40 | S10.3 | The Immune Evolution of Hereditary Colorectal Cancers - New Concepts and Clinical Implications
<i>Matthias Kloor, Germany</i> |
| 15:00 | | Discussion |

15:15 – 15:45

Break

MONDAY 11 MARCH

15:45 – 17:00

Session 11: Curative treatment of metastases

Chairs: Eduardo Barosso, Pieter Tanis

- | | | |
|-------|-------|---|
| 15:45 | S11.1 | Controversies in loco-regional therapy of peritoneal metastases:
What is really needed?
<i>Niels Kok, the Netherlands</i> |
| 16:05 | S11.2 | Liver-directed therapies (Hepatic arterial infusion, SIRT):
What to use when?
<i>Bas Groot Koerkamp, the Netherlands</i> |
| 16:25 | S11.3 | Spectrum of treatments for lung metastases:
SBRT, RFA, resection or no local therapy at all?
<i>Dirk Van Raemdonck, Belgium</i> |
| 16:45 | | Discussion |
| 17:00 | | Closing |

GASTROENTEROLOGY PARALLEL PROGRAM

Sunday 10 March

Meetingroom 1.08

10:30 – 12:30

Pathology

- | | | |
|-------|------|--|
| 10:30 | G1.1 | Should Tumor budding be included in the risk prediction algorithms
<i>Alessandro Lugli, Switzerland</i> |
| 11:00 | G1.2 | Evolution to early carcinoma-lessons for lymph node metastasis
<i>Lennard Lee, United Kingdom</i> |
| 11:30 | G1.3 | What is a sufficient resection margin
<i>Maurice Loughrey, Ireland</i> |
| 12:00 | G1.4 | Observer variation for histologic risk predictors
<i>Miangele Lacle, the Netherlands</i> |

12:30 – 14:00

Lunch

14:00 – 15:45

Resection

- | | | |
|-------|------|---|
| 14:00 | G1.5 | Cut-off level for en bloc resections?
<i>Yara Backes, the Netherlands</i> |
| 14:30 | G1.6 | ESD or TEM/TAMIS?
<i>Eelco de Graaf, the Netherlands</i> |
| 15:00 | G1.7 | eFTR, ESD or limited surgical wedge excision
<i>Francisco Baldaque Silva, Sweden</i> |
| 15:30 | G1.8 | Wait and see of high risk T1 CRCs
<i>Regina Beets-Tan & Roel Hompes, the Netherlands</i> |



RADIOLOGY PARALLEL PROGRAM

Monday 11 March

Meetingroom 1.08

09:45 – 10:45

Workshop on imaging of rectal cancer, lectures, interactive case based discussions

09:45

R1.1

Organ preservation: the surgeon's view
Geerard Beets, the Netherlands

10:05

R1.2

Diffusion weighted MRI and its role in Organ preservation
Doenja Lambregts, the Netherlands

10:25

R1.3

Radiomics in rectal cancer
Joost van Griethuysen, the Netherlands

10:45 – 11:15

Break

11:15 – 12:30

Case based panel discussions

12:30 – 14:00

Lunch

14:00 – 15:15

Workshop on imaging and treatment of colorectal Liver metastases

14:00

R1.4

Image evaluation of advanced colorectal cancer in the era of targeted and locoregional therapies
Riccardo Manfredi, Italy

14:20

R1.5

New trends in the systemic treatments of advanced colorectal cancer
Andres Cervantes, Spain

14:40

R1.6

Navigation surgery and open ablative therapies in colorectal metastases in the liver
Theo Ruers, the Netherlands

15:00

R1.7

The role of interventional radiology out of the guidelines for patients with metastatic colorectal cancer
Fernando Gómez Muñoz, Spain